Publications by authors named "Thomas Geldart"

Claim this Profile
A
A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data.
Parneet Cheema, Byoung Chul Cho, Helano Freitas, Mariano Provencio, Yuh Min Chen, Thomas Geldart

Future Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy.
Peter E Hall, Scott T C Shepherd, Janet Brown, James Larkin, Robert Jones, Thomas Geldart

Eur Urol Focus· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss.
Simon J Crabb, Karen Martin, Julia Abab, Ian Ratcliffe, Roger Thornton, Thomas Geldart

Eur J Cancer· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
Thomas Powles, Matthew Wheater, Omar Din, Thomas Geldart, Ekaterini Boleti

Eur Urol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma.
Thomas Geldart, John Chester, Angela Casbard, Simon Crabb, Tony Elliott

Eur Urol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure.
Thomas R Geldart, Joanna Gale, Joe McKendrick, Julie Kirby, Graham Mead

BJU Int· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks.
Peter Johnson, Thomas Geldart, Pierre Fumoleau, Marie-Claire Pinel, Laurent Nguyen

Invest New Drugs· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis